Literature DB >> 1271190

Histocompatibility antigens in childhood-onset arthritis.

J G Schaller, H D Ochs, E D Thomas, B Nisperos, P Feigl, R J Wedgwood.   

Abstract

One hundred and twelve well-studied patients with a prior diagnosis of juvenile rheumatoid arthritis were differentiated into seven clinically distinct subgroups, including a group in whom recognizable ankylosing spondylitis had developed by time of follow-up. An apparent increased prevalence of HLA-B27 in the entire series (26%) was clearly related to its increased prevalence in only two subgroups: patients whose disease had progressed to overt ankylosing spondylitis (five of five patients) and boys with pauciarticular arthritis whose disease would be consistent with early ankylosing spondylitis (11 of 18 patients). There were no significant associations of B27 with systemic onset JRA, polyarticular JRA, pauciarticular JRA in girls, or JRA with chronic iridocyclitis. The only other significant alterations found were increased prevalences of HLA-A2 and HLA-BW15 in patients with polyarticular disease without identifiable rheumatoid factor. This study emphasizes that the clinical disorders included under the category of juvenile rheumatoid arthritis represent more than a single disease and that this heterogeneity must be considered in interpreting studies such as those of histocompatibility typing.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1271190     DOI: 10.1016/s0022-3476(76)81043-8

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  10 in total

Review 1.  Classification of juvenile spondyloarthritis: Enthesitis-related arthritis and beyond.

Authors:  Robert A Colbert
Journal:  Nat Rev Rheumatol       Date:  2010-07-06       Impact factor: 20.543

2.  Inherited predisposition to iridocyclitis with juvenile rheumatoid arthritis: selectivity among HLA-DR5 haplotypes.

Authors:  M L Miller; P A Fraser; J M Jackson; M G Larson; R A Petersen; L T Chylack; D N Glass
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

3.  Clinical, HLA, and roentgenological follow up study of patients with juvenile arthritis: comparison between the long term outcome of transient and persistent arthritis in children.

Authors:  H Ström; N Lindvall; B Hellström; L Rosenthal
Journal:  Ann Rheum Dis       Date:  1989-11       Impact factor: 19.103

Review 4.  [Genetic background of juvenile idiopathic arthritis].

Authors:  J P Haas
Journal:  Z Rheumatol       Date:  2010-08       Impact factor: 1.372

Review 5.  Atypical spondyloarthritis in children: proposed diagnostic criteria.

Authors:  A Hussein; H Abdul-Khaliq; H von der Hardt
Journal:  Eur J Pediatr       Date:  1989-04       Impact factor: 3.183

6.  [Juvenile rheumatoid arthritis and HLA-B27].

Authors:  G Mathon; C Paré; H Ménard; L Tétreault; M Camerlain
Journal:  Can Med Assoc J       Date:  1980-09-06       Impact factor: 8.262

7.  HLA-DP/DR interaction in early onset pauciarticular juvenile chronic arthritis.

Authors:  C Paul; U Schoenwald; H Truckenbrodt; M P Bettinotti; G Brünnler; E Keller; C Nevinny-Stickel; Z Yao; E D Albert
Journal:  Immunogenetics       Date:  1993       Impact factor: 2.846

8.  HLA studies in IgM rheumatoid-factor-positive arthritis of childhood.

Authors:  L E Clemens; E Albert; B M Ansell
Journal:  Ann Rheum Dis       Date:  1983-08       Impact factor: 19.103

9.  Early-onset pauciarticular juvenile rheumatoid arthritis associated with human leukocyte antigen-DRw5, iritis, and antinuclear antibody.

Authors:  D Glass; D Litvin; K Wallace; L Chylack; M Garovoy; C B Carpenter; P H Schur
Journal:  J Clin Invest       Date:  1980-09       Impact factor: 14.808

10.  The assessment of the spondyloarthritis international society concept and criteria for the classification of axial spondyloarthritis and peripheral spondyloarthritis: A critical appraisal for the pediatric rheumatologist.

Authors:  Ruben Burgos-Vargas
Journal:  Pediatr Rheumatol Online J       Date:  2012-05-31       Impact factor: 3.054

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.